# Identification of a Novel Target for the Treatment of Endometriosis-associated Pain

> **NIH NIH R21** · BOSTON CHILDREN'S HOSPITAL · 2022 · $265,500

## Abstract

Endometriosis is an inflammatory disease characterized by the presence of endometrium-like lesions and
progressive abdominal or pelvic pain. It affects ~10% of women of childbearing age and ~30% of patients are
not effectively treated by existing options; new therapeutics are desperately needed. We have developed and
validated a mouse model of endometriosis pain. Using that model, we discovered that the specific pro-
resolving lipid mediator (SPM) protectin DX (PDX) rapidly abolishes endometriosis-associated pain and shrinks
lesions. Unfortunately, poor stability and pharmacokinetic properties render PDX a poor drug lead. To
leverage the anti-endometriosis activity of PDX, its receptor must be identified. All SPMs for which a high
affinity receptor is known activate G-protein coupled receptors (GPCRs). Thus we hypothesize that PDX acts
through a GPCR and aim to identify it and the cell type(s) expressing the PDX receptor.
 We will identify the mechanism by which protectin DX acts by using the PRESTO-Tango system to
measure arrestin activation in a comprehensive library of human non-olfactory GPCRs. We will then identify
the G-protein(s) that couple to this GPCR in the context of PDX signaling. To confirm that this is the relevant
receptor, we will measure the effect of ablating this GPCR on the PDX-mediated increase in efferocytosis and
up regulation of M2 markers in RAW264.7 cells. Next, we will seek to identify the cell types that mediate the
anti-endometriosis effects of multiple SPMs, including MaR1, RvD5, and PDX. To that end, we will use single-
cell RNAseq (scRNAseq) to identify cell types that express SPM receptors in our mouse model of
endometriosis-associated pain at a relevant timepoint. We will also measure the effect of PDX on the
transcriptional profile of relevant cell types in vivo, in order to begin to understand how PDX relieves pain and
reduces lesion size. Then, we will use available resources to confirm expression of these receptors in cells
human lesions.
 When these experiments are complete, we will have identified a novel, druggable target for endometriosis
therapy. As this is expected to be a GPCR, common strategies like high-throughput screening (with which we
have experience) can then be used to identify pharmacophores that lack the liabilities present in PDX, itself.
We will also identify pharmacodynamic markers of protectin DX activity that will allow target engagement to be
measured during a therapeutic development program. Although additional target validations work (e.g. with
knockout mice) will remain, these studies will provide important knowledge about the mechanism by which
SPMs, including PDX, reduce endometriosis-associated pain and lesion growth. Thus, the knowledge to be
gained by these studies will represent an important advance toward the development of desperately needed
novel therapeutics for endometriosis.

## Key facts

- **NIH application ID:** 10508963
- **Project number:** 1R21HD109491-01
- **Recipient organization:** BOSTON CHILDREN'S HOSPITAL
- **Principal Investigator:** MICHAEL SEAN ROGERS
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $265,500
- **Award type:** 1
- **Project period:** 2022-09-15 → 2024-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10508963

## Citation

> US National Institutes of Health, RePORTER application 10508963, Identification of a Novel Target for the Treatment of Endometriosis-associated Pain (1R21HD109491-01). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10508963. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*